AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

The interventions being tested include risankizumab, ABBV-382, and lutikizumab. These drugs are administered either as subcutaneous injections or intravenous infusions, with the goal of reducing ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of ...

Skyrizi (risankizumab) was previously already cleared by the FDA for adults with moderately to severely active Crohn's disease, active psoriatic arthritis, and moderate to severe plaque psoriasis.

J&J says oral IL-23 inhibitor JNJ-2113 shows a durable effect in psoriasis, making it a potential companion to its injectable Tremfya.

In addition to Cantor Fitzgerald, AbbVie also received a Buy from Piper Sandler’s David Amsellem in a report issued yesterday. However, on August 4, Bernstein maintained a Hold rating on AbbVie (NYSE: ...

Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...